Apellis Pharmaceuticals (APLS) Revenue & Revenue Breakdown
Apellis Pharmaceuticals Revenue Highlights
Latest Revenue (Y)
$366.28M
Latest Revenue (Q)
$179.14M
Main Segment (Y)
Product
Apellis Pharmaceuticals Revenue by Period
Apellis Pharmaceuticals Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $366.28M | 385.64% |
| 2022-12-31 | $75.42M | 13.31% |
| 2021-12-31 | $66.56M | -73.44% |
| 2020-12-31 | $250.65M | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2016-12-31 | - | 100.00% |
| 2015-12-31 | - | 100.00% |
| 2014-12-31 | - | 100.00% |
| 2013-12-31 | - | - |
Apellis Pharmaceuticals generated $366.28M in revenue during NA 2023, up 385.64% compared to the previous quarter, and up Infinity% compared to the same period a year ago.
Apellis Pharmaceuticals Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | $179.14M | 3.95% |
| 2024-03-31 | $172.32M | 17.73% |
| 2023-12-31 | $146.38M | 47.58% |
| 2023-09-30 | $99.18M | 4.44% |
| 2023-06-30 | $94.97M | 111.77% |
| 2023-03-31 | $44.85M | 97.88% |
| 2022-12-31 | $22.66M | 2.75% |
| 2022-09-30 | $22.06M | 35.13% |
| 2022-06-30 | $16.32M | 13.50% |
| 2022-03-31 | $14.38M | -76.15% |
| 2021-12-31 | $60.29M | 967.08% |
| 2021-09-30 | $5.65M | 806.90% |
| 2021-06-30 | $623.00K | 100.00% |
| 2021-03-31 | - | -100.00% |
| 2020-12-31 | $250.00M | 38599.69% |
| 2020-09-30 | $646.00K | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | -100.00% |
| 2019-12-31 | $-142.15K | 100.00% |
| 2019-09-30 | - | 100.00% |
| 2019-06-30 | - | 100.00% |
| 2019-03-31 | - | -100.00% |
| 2018-12-31 | $11.54K | 100.00% |
| 2018-09-30 | - | 100.00% |
| 2018-06-30 | - | 100.00% |
| 2018-03-31 | - | -100.00% |
| 2017-12-31 | $11.54K | 100.00% |
| 2017-09-30 | - | 100.00% |
| 2017-06-30 | - | 100.00% |
| 2017-03-31 | - | 100.00% |
| 2016-12-31 | - | 100.00% |
| 2016-09-30 | - | 100.00% |
| 2015-12-31 | - | 100.00% |
| 2015-09-30 | - | 100.00% |
| 2014-12-31 | - | 100.00% |
| 2014-09-30 | - | - |
Apellis Pharmaceuticals generated $179.14M in revenue during Q2 2024, up 3.95% compared to the previous quarter, and up 399.45% compared to the same period a year ago.
Apellis Pharmaceuticals Revenue Breakdown
Apellis Pharmaceuticals Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 23 | Dec 22 | Dec 21 | Dec 20 |
|---|---|---|---|---|
| Product | $366.28M | $65.09M | $15.15M | - |
| Licensing And Other Revenue | $30.31M | $10.33M | $51.42M | - |
| Collaboration | - | - | - | $152.00K |
Apellis Pharmaceuticals's latest annual revenue breakdown by segment (product or service), as of Dec 23: Product (92.36%), and Licensing And Other Revenue (7.64%).
Quarterly Revenue by Product
| Product/Service | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product | $179.14M | $163.07M | $138.65M | $99.18M | $89.64M | $38.80M | $19.65M | $17.68M | $15.65M | $12.11M | $9.21M | $5.31M |
| Licensing And Other Revenue | $20.55M | $9.25M | $7.72M | $11.22M | $5.32M | $6.05M | $3.01M | $4.38M | $668.00K | $2.27M | $51.08M | $336.00K |
Apellis Pharmaceuticals's latest quarterly revenue breakdown by segment (product or service), as of Jun 24: Product (89.71%), and Licensing And Other Revenue (10.29%).
Apellis Pharmaceuticals Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| AMLX | Amylyx Pharmaceuticals | $380.79M | $88.64M |
| APLS | Apellis Pharmaceuticals | $366.28M | $179.14M |
| BPMC | Blueprint Medicines | $249.38M | $138.16M |
| MREO | Mereo BioPharma Group | $10.00M | - |
| RXDX | Prometheus Biosciences | $6.81M | $1.10M |
| XFOR | X4 Pharmaceuticals | - | $563.00K |
| IMVT | Immunovant | - | - |
| DAWN | Day One Biopharmaceuticals | - | $8.19M |
| ABOS | Acumen Pharmaceuticals | - | - |
| INZY | Inozyme Pharma | - | - |
| CERE | Cerevel Therapeutics | - | - |
| MDGL | Madrigal Pharmaceuticals | - | - |
| TERN | Terns Pharmaceuticals | - | - |
| AKRO | Akero Therapeutics | - | - |
APLS Revenue FAQ
What is Apellis Pharmaceuticals’s yearly revenue?
Apellis Pharmaceuticals's yearly revenue for 2023 was $366.28M, representing an increase of 385.64% compared to 2022. The company's yearly revenue for 2022 was $75.42M, representing an increase of 13.31% compared to 2021. APLS's yearly revenue for 2021 was $66.56M, representing a decrease of -73.44% compared to 2020.
What is Apellis Pharmaceuticals’s quarterly revenue?
Apellis Pharmaceuticals's quarterly revenue for Q2 2024 was $179.14M, a 3.95% increase from the previous quarter (Q1 2024), and a 88.63% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $172.32M, a 17.73% increase from the previous quarter (Q4 2023), and a 284.26% increase year-over-year (Q1 2023). APLS's quarterly revenue for Q4 2023 was $146.38M, a 47.58% increase from the previous quarter (Q3 2023), and a 545.89% increase year-over-year (Q4 2022).
What is Apellis Pharmaceuticals’s revenue growth rate?
Apellis Pharmaceuticals's revenue growth rate for the last 3 years (2021-2023) was 450.28%, and for the last 5 years (2019-2023) was 0%.
What are Apellis Pharmaceuticals’s revenue streams?
Apellis Pharmaceuticals's revenue streams in c 23 are Product, and Licensing And Other Revenue. Product generated $366.28M in revenue, accounting 92.36% of the company's total revenue, up 462.71% year-over-year. Licensing And Other Revenue generated $30.31M in revenue, accounting 7.64% of the company's total revenue, up 193.42% year-over-year.
What is Apellis Pharmaceuticals’s main source of revenue?
For the fiscal year ending Dec 23, the largest source of revenue of Apellis Pharmaceuticals was Product. This segment made a revenue of $366.28M, representing 92.36% of the company's total revenue.